Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Study ID
- NCT05051059
- Status
- Recruiting
Conditions
- Bone Sarcoma
- Soft Tissue Sarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 95 Years
- Healthy Volunteers
- Accepted
Interventions
- Functional outcome — OTHER3D-motion analysis and strength assessment
- Health related quality of life (HRQoL) assessment — OTHERQuality of Life Questionnaire C-30 (QLQ-C30), Impact on Participation and Autonomy Questionnaire (IPAQ) and Musculoskeletal Tumor Society Score (MSTS)
Study Details
Primary bone and soft tissue sarcomas are an exceptionally rare form of cancer, collectively accounting for only 1% of all malignancies diagnosed. Sarcomas often occur in the patients' extremities and treatment typically involves limb salvage surgery with bone and/or muscle resection. These surgeries often leave the patients with disfigurements, psychological trauma, and functional disabilities. Perhaps, the most difficult and life-altering decision that patients (and their parents) with primary bone sarcomas about the knee joint have to make, involves choosing the type of surgical procedure that will provide them with the outcome that meets their functional as well as aesthetic expectations. In literature, the quality of life for patients with osteosarcoma around the knee joint after three different surgical procedures, that is, amputation, endoprosthetic reconstruction and rotationplasty was evaluated. There was found that patients treated with rotationplasty showed significantly higher functional scores compared to the two other groups of patients. Also, researchers investigated the long-term quality of life after bone sarcoma surgery around the knee joint and found that, despite the functional disability, survivors were busy with work, study, relationships, and sometimes they have founded a family. Most published reports in the literature on assessment of gait in the lower-extremity sarcoma survivors were focused on bone sarcoma patients after wide resection and endoprosthetic reconstruction. To the knowledge of the investigator, there has been no published studies on gait analysis after resection of soft tissue sarcomas (STS) of the lower extremity. The rare and heterogeneous aspects of STS and the paucity of knowledge of movement strategies in these patients hinder the development of effective rehabilitation protocols for recovering movement after resection of STS in the lower limb.
Key Dates
- First listed
- Sep 21, 2021
- Start date
- Oct 1, 2021
- Status verified
- Mar 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Other: Soft tissue sarcoma of the thighPatients who underwent surgical resection of a deep intramuscular soft tissue sarcoma of the thigh
- No Intervention: Control groupA group of healthy age-matched individuals will be identified out of an available gait lab database to compare the gait pattern with tha of the patient group
- Other: Bone or soft tissue sarcoma of the lower extremityPatients who underwent surgical resection of a bone or soft tissue sarcoma of the lower extremity
Primary Outcome Measure
Musculoskeletal Tumor Society Score (MSTS) [ Time Frame: Within a period of 1 year ]
Central Contacts
- Hazem Wafa+32 16 33 88 73
- Moke Lieven+32 16 34 08 84
Related Studies
- LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic OncologyPHASE4 · Enrolling By Invitation · Massachusetts General Hospital · Los Angeles, California
- Assessment of Healing and Function After Reconstruction Surgery for Bone SarcomasRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway AlterationPHASE2 · Recruiting · Medical College of Wisconsin · Jacksonville, Florida
- Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue SarcomaPHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York